Sangamo BioSciences Inc. (NASDAQ:SGMO) shares were up 4.3% on Wednesday . The stock traded as high as $6.16 and last traded at $6.08, with a volume of 311,085 shares. The stock had previously closed at $5.83.

Several research analysts have recently weighed in on SGMO shares. Jefferies Group restated a “buy” rating and issued a $14.00 price target on shares of Sangamo BioSciences in a research note on Thursday, June 9th. Zacks Investment Research cut Sangamo BioSciences from a “hold” rating to a “sell” rating in a research note on Tuesday, July 5th. Wells Fargo & Co. started coverage on Sangamo BioSciences in a research note on Tuesday, May 3rd. They issued a “buy” rating for the company. Finally, Wedbush restated an “outperform” rating and issued a $30.00 price target on shares of Sangamo BioSciences in a research note on Friday, May 6th. One equities research analyst has rated the stock with a sell rating and seven have assigned a buy rating to the stock. The stock has a consensus rating of “Buy” and an average target price of $16.75.

The stock’s market capitalization is $446.92 million. The company’s 50 day moving average price is $5.92 and its 200-day moving average price is $6.08.

Sangamo BioSciences (NASDAQ:SGMO) last announced its earnings results on Monday, May 2nd. The biopharmaceutical company reported ($0.23) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.24) by $0.01. During the same period last year, the business posted ($0.08) EPS. The company had revenue of $3.94 million for the quarter, compared to the consensus estimate of $5.49 million. The firm’s revenue was down 70.8% compared to the same quarter last year. On average, equities analysts forecast that Sangamo BioSciences Inc. will post ($0.98) EPS for the current year.

An institutional investor recently raised its position in Sangamo BioSciences stock. Royce & Associates LLC increased its stake in shares of Sangamo BioSciences Inc. (NASDAQ:SGMO) by 47.1% during the fourth quarter, according to its most recent filing with the SEC. The fund owned 312,100 shares of the biopharmaceutical company’s stock after buying an additional 100,000 shares during the period. Royce & Associates LLC owned 0.45% of Sangamo BioSciences worth $2,849,000 at the end of the most recent quarter.

Sangamo Biosciences Inc is a clinical-stage biopharmaceutical company. The Company is focused on research, development and commercialization of engineered deoxyribonucleic acid (DNA)-binding proteins for therapeutic genome editing and gene regulation. It is engaged in developing zinc finger DNA-binding proteins (ZFP) therapeutics.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.